Answers are grounded in this paper and cite their sources.
T-cell engagers (TCEs) are bispecific or multispecific immunotherapeutic molecules that specifically bridge and activate T cells to mediate tumor cell killing. Although TCEs have achieved remarkable clinical success in hematological malignancies, their efficacy in solid tumors remains limited by physical tumor barriers, an immunosuppressive tumor microenvironment, antigen heterogeneity, and off-tumor toxicity. This review systematically summarizes recent engineering strategies for TCEs in solid tumors, including miniaturization and novel expression and delivery technologies to enhance tumor penetration, affinity optimization, integration of costimulatory signals and immune checkpoint blockade, and tumor microenvironment-responsive prodrug designs to balance antitumor immune activity with treatment safety, as well as novel molecular architectures to overcome tumor antigen escape and heterogeneity. We further discuss biomarker-guided patient selection and engineering strategy selection, together with developability and chemistry, manufacturing, and controls (CMC) considerations for clinical translation, and highlight future directions toward precise activation, multimodal synergy, and efficient local enrichment, providing a framework for rational development of TCE-based immunotherapy for solid tumors.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: